Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11183676 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL9337698 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL15303130 | 0.91 | ITGB3 (0.52) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL863032 | 0.87 | KMT2A (0.51) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL25197154 | 0.86 | KMT2A (0.51) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL16791358 | 0.86 | KMT2A (0.51) | ITGB3ITGA2BLMNAPPARGKMT2A | |
| SCHEMBL10660397 | 0.86 | ITGB3 (0.64) | ITGB3ITGA2BLMNAKMT2AFPR2 | |
| SCHEMBL6438360 | 0.86 | ITGB3 (0.64) | ITGB3ITGA2BLMNAKMT2AFPR2 | |
| SCHEMBL4361126 | 0.86 | ITGB3 (0.64) | ITGB3ITGA2BLMNAKMT2AFPR2 | |
| SCHEMBL8472484 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BLMNAPPARGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015168368-A1 | FLUOROALKYLATION REAGENTS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-11-05 | — | — | WO | disclosed |
| US-5981558-A | ANTIMICROBIAL ACTIVITY AND ANTITUMOR ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0918058-A1 | DC 107 DERIVATIVES (1) | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-05-26 | — | — | EP | disclosed |
| EP-0249434-B1 | Peptide derivatives and processes for their preparation | VYZK USTAV FARM BIOCHEM SP (CZ) | 1994-05-04 | — | — | EP | disclosed |
| US-4898930-A | Peptide derivatives and processes for their preparation | SPOFA, SPOJENE PODNIKY PRO (CS) | 1990-02-06 | — | — | US | disclosed |
| EP-0249434-A2 | Peptide derivatives and processes for their preparation | Vyzkumny ustav pro farmacii a biochemii (CZ) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | ITGB3 1141/4885ITGA2B 819/4885LMNA 950/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | ITGB3 959/4885ITGA2B 803/4885LMNA 843/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | ITGB3 278/4885ITGA2B 346/4885LMNA 703/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | ITGB3 278/4885ITGA2B 346/4885LMNA 703/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | ITGB3 959/4885ITGA2B 803/4885LMNA 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.